现有和未来的实践进展:芳酶抑制剂诱导的关节痛
Sara Kim1, Nan Chen2, Pankti Reid3
1Department of Medicine, University of Chicago, Chicago, IL, USA.
Rheumatology advances in practice
|April 11, 2024
概括
芳酶抑制剂诱导的关节痛影响近40%的乳腺癌患者,经常导致治疗中止. 像维生素D3,duloxetine,针,炼或切换AI这样的策略可以管理关节疼痛并改善坚持.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 芳香酶抑制剂 (AIs) 是对绝经后妇女激素受体阳性乳腺癌的有效辅助疗法.
- 人工智能引起的关节痛 (AI-induced arthralgia,简称AIA) 是一种常见的毒性,导致治疗坚持不良和停止治疗.
- 了解AIA对于优化乳腺癌治疗结果至关重要.
研究的目的:
- 审查和综合当前关于人工智能引起的关节痛的知识.
- 确定AIA的发病率,风险因素和管理策略.
主要方法:
- 对有关芳酶抑制剂诱导的关节痛的现有文献进行系统审查.
- 对发病率,风险因素和治疗结果的分析.
主要成果:
- AIA的平均发病率为39.1%,其中9.3%的人因AIA而停止AI治疗.
- 非炎症性关节痛是最常见的;自上次月经以来的较短时间和先前存在的关节疼痛被确定为危险因素.
- 维生素D3,duloxetine,针和运动显示出潜在的益处,并转换为替代AI改善了症状.
结论:
- AIA是乳腺癌治疗的一个重大挑战,影响了治疗的坚持和延续.
- 一些干预措施,包括药理和非药理方法,在管理AIA方面表现出有效性.
- 对预测生物标志物和更强大的治疗选择进行进一步的研究是必要的,以改善患者管理.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


